Presentations from the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting, 2016.
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain
TRV130, a G Protein-biased Ligand of the µ-opioid Receptor, Demonstrates Analgesic Efficacy Following Bunionectomy in an Adaptive Phase 2 Study
Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155(9):1829-35, September 2014.
Biased ligands at G protein-coupled receptors: promise and progress. Trends in Pharmacological Sciences 35(7):308-16, July 2014
A comparison of the pharmacokinetics and pharmacodynamics of TRV130 vs. morphine in healthy volunteers. Presented at the 2014 American Pain Society meeting.
First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers. The Journal of Clinical Pharmacology 54(3) 351–357. March 2014.
Structure-Activity Relationships and Discovery of a G Protein Biased Mu Opioid Receptor Ligand, TRV130, for the Treatment of Acute Severe Pain.
A G Protein-Biased Ligand at the mu opioid Receptor is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine. J Pharmacol Exp Ther 344:708-717, March 2013.
First human dosing experience with TRV130, a G protein biased ligand at the mu opioid receptor. Presented at 2013 American Academy of Neurology meeting
A G protein biased mu opioid receptor ligand elicits potent analgesia but reduced constipation & respiratory depression compared to morphine in rodents. Presented at the 2012 American Association of Pain Medicine Meeting
Copyright © Trevena, Inc.